A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT)

Status: Recruiting

Phase of Trial: Phase III/IV

Latest Information Update: 13 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydralazine/isosorbide dinitrate (Primary) ; Metformin (Primary)
Indications Chronic heart failure
Focus Therapeutic Use
Acronyms DANHEART; DanHeart (H-HeFT / Met-HeFT); DanHeart (H-HeFT / Met-HeFT)

Most Recent Events

07 Oct 2022 Planned End Date changed from 1 Sep 2023 to 31 Dec 2026.
07 Oct 2022 Planned primary completion date changed from 1 Mar 2023 to 31 Dec 2026.
08 Oct 2020 Trial design (n=296; as of May 2020) published in the American Heart Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight